AtopyReg®,意大利成人中重度特应性皮炎前瞻性患者登记:基线人口学、疾病特征、合并症和治疗史。

IF 8.6 1区 医学 Q1 DERMATOLOGY
Luca Stingeni, Andrea Chiricozzi, Piergiacomo Calzavara-Pinton, Maddalena Napolitano, Ketty Peris, Donatella Schena, Cataldo Patruno, Mariateresa Rossi, Caterina Foti, Maria C. Fargnoli, Monica Corazza, Silvia M. Ferrucci, Paolo D. Pigatto, Marco Romanelli, Gabriella Fabbrocini, Giampiero Girolomoni, Maria Passante, Paolo Romita, Maria Esposito, Natale Schettini, Angelo V. Marzano, Giulia Tonini, Rossella Marietti, Gabriele Casciola, Giuseppe Argenziano, Katharina Hansel, AtopyReg® study group
{"title":"AtopyReg®,意大利成人中重度特应性皮炎前瞻性患者登记:基线人口学、疾病特征、合并症和治疗史。","authors":"Luca Stingeni,&nbsp;Andrea Chiricozzi,&nbsp;Piergiacomo Calzavara-Pinton,&nbsp;Maddalena Napolitano,&nbsp;Ketty Peris,&nbsp;Donatella Schena,&nbsp;Cataldo Patruno,&nbsp;Mariateresa Rossi,&nbsp;Caterina Foti,&nbsp;Maria C. Fargnoli,&nbsp;Monica Corazza,&nbsp;Silvia M. Ferrucci,&nbsp;Paolo D. Pigatto,&nbsp;Marco Romanelli,&nbsp;Gabriella Fabbrocini,&nbsp;Giampiero Girolomoni,&nbsp;Maria Passante,&nbsp;Paolo Romita,&nbsp;Maria Esposito,&nbsp;Natale Schettini,&nbsp;Angelo V. Marzano,&nbsp;Giulia Tonini,&nbsp;Rossella Marietti,&nbsp;Gabriele Casciola,&nbsp;Giuseppe Argenziano,&nbsp;Katharina Hansel,&nbsp;AtopyReg® study group","doi":"10.1007/s40257-023-00819-y","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Objective</h3><p>AtopyReg<sup>®</sup> is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST). We aimed to describe baseline demographics, disease characteristics, comorbidities, and therapeutic data of adult patients affected by moderate-to-severe atopic dermatitis.</p><h3>Methods</h3><p>Patients were selected based on the following inclusion criteria: age ≥ 18 years; Eczema Area and Severity Index score ≥ 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a Numeric Rating Scale itch score ≥ 7 or a Numeric Rating Scale sleep loss score ≥ 7, or a Dermatology Life Quality Index score ≥ 10. Demographic and clinical data at baseline were recorded and analyzed.</p><h3>Results</h3><p>A total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18–90 years) were enrolled by 12 Italian Dermatology Units between January 2019 and November 2022. Skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). Mean Eczema Area and Severity Index score was 22.3, mean Dermatology Life Quality Index value was 17.6, mean Patient Oriented Eczema Measure score was 13.1, and mean Numeric Rating Scale itch and sleep loss scores were 7.6 and 5.9, respectively. Previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients.</p><h3>Conclusions</h3><p>This baseline data analysis deriving from AtopyReg<sup>®</sup> provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients’ quality of life.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"25 1","pages":"149 - 160"},"PeriodicalIF":8.6000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796485/pdf/","citationCount":"0","resultStr":"{\"title\":\"AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History\",\"authors\":\"Luca Stingeni,&nbsp;Andrea Chiricozzi,&nbsp;Piergiacomo Calzavara-Pinton,&nbsp;Maddalena Napolitano,&nbsp;Ketty Peris,&nbsp;Donatella Schena,&nbsp;Cataldo Patruno,&nbsp;Mariateresa Rossi,&nbsp;Caterina Foti,&nbsp;Maria C. Fargnoli,&nbsp;Monica Corazza,&nbsp;Silvia M. Ferrucci,&nbsp;Paolo D. Pigatto,&nbsp;Marco Romanelli,&nbsp;Gabriella Fabbrocini,&nbsp;Giampiero Girolomoni,&nbsp;Maria Passante,&nbsp;Paolo Romita,&nbsp;Maria Esposito,&nbsp;Natale Schettini,&nbsp;Angelo V. Marzano,&nbsp;Giulia Tonini,&nbsp;Rossella Marietti,&nbsp;Gabriele Casciola,&nbsp;Giuseppe Argenziano,&nbsp;Katharina Hansel,&nbsp;AtopyReg® study group\",\"doi\":\"10.1007/s40257-023-00819-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and Objective</h3><p>AtopyReg<sup>®</sup> is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST). We aimed to describe baseline demographics, disease characteristics, comorbidities, and therapeutic data of adult patients affected by moderate-to-severe atopic dermatitis.</p><h3>Methods</h3><p>Patients were selected based on the following inclusion criteria: age ≥ 18 years; Eczema Area and Severity Index score ≥ 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a Numeric Rating Scale itch score ≥ 7 or a Numeric Rating Scale sleep loss score ≥ 7, or a Dermatology Life Quality Index score ≥ 10. Demographic and clinical data at baseline were recorded and analyzed.</p><h3>Results</h3><p>A total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18–90 years) were enrolled by 12 Italian Dermatology Units between January 2019 and November 2022. Skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). Mean Eczema Area and Severity Index score was 22.3, mean Dermatology Life Quality Index value was 17.6, mean Patient Oriented Eczema Measure score was 13.1, and mean Numeric Rating Scale itch and sleep loss scores were 7.6 and 5.9, respectively. Previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients.</p><h3>Conclusions</h3><p>This baseline data analysis deriving from AtopyReg<sup>®</sup> provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients’ quality of life.</p></div>\",\"PeriodicalId\":7706,\"journal\":{\"name\":\"American Journal of Clinical Dermatology\",\"volume\":\"25 1\",\"pages\":\"149 - 160\"},\"PeriodicalIF\":8.6000,\"publicationDate\":\"2023-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796485/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40257-023-00819-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Dermatology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40257-023-00819-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:AtopyReg®是意大利皮肤性病学会(SIDeMaST)于2018年推动的一项针对成人中重度特应性皮炎的多中心、前瞻性、观察性、非营利队列研究。我们旨在描述受中度至重度特应性皮炎影响的成年患者的基线人口统计学、疾病特征、合并症和治疗数据。方法:根据以下纳入标准选择患者:年龄≥18岁;湿疹面积和严重程度指数评分≥16,或定位在可见或敏感区域(面部、颈部、手部或生殖器),或瘙痒评分≥7,或睡眠损失评分≥7或皮肤病生活质量指数评分≥10。记录并分析基线时的人口统计学和临床数据。结果:2019年1月至2022年11月,共有1170名患者(男性51.1%;平均年龄:44.7岁;年龄范围18-90岁)入选意大利12个皮肤科。83.2%的患者的皮肤病变是湿疹样的,最常见的部位是弯曲(53.9%)、面部(50.9%)和颈部(48.0%)。湿疹面积和严重程度指数平均得分为22.3,皮肤科生活质量指数平均值为17.6,以患者为导向的湿疹测量平均得分为13.1,瘙痒和睡眠损失评分分别为7.6和5.9。以前的全身治疗是77.7%的患者使用皮质类固醇,50.3%的患者使用抗组胺药,42.6%的患者使用环孢菌素A。结论:这项源自AtopyReg®的基线数据分析为意大利中重度特应性皮炎患者提供了真实的证据,证实了特应性皮肤炎的高负担对患者的生活质量有重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Background and Objective

AtopyReg® is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST). We aimed to describe baseline demographics, disease characteristics, comorbidities, and therapeutic data of adult patients affected by moderate-to-severe atopic dermatitis.

Methods

Patients were selected based on the following inclusion criteria: age ≥ 18 years; Eczema Area and Severity Index score ≥ 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a Numeric Rating Scale itch score ≥ 7 or a Numeric Rating Scale sleep loss score ≥ 7, or a Dermatology Life Quality Index score ≥ 10. Demographic and clinical data at baseline were recorded and analyzed.

Results

A total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18–90 years) were enrolled by 12 Italian Dermatology Units between January 2019 and November 2022. Skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). Mean Eczema Area and Severity Index score was 22.3, mean Dermatology Life Quality Index value was 17.6, mean Patient Oriented Eczema Measure score was 13.1, and mean Numeric Rating Scale itch and sleep loss scores were 7.6 and 5.9, respectively. Previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients.

Conclusions

This baseline data analysis deriving from AtopyReg® provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients’ quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.20
自引率
2.70%
发文量
84
审稿时长
>12 weeks
期刊介绍: The American Journal of Clinical Dermatology is dedicated to evidence-based therapy and effective patient management in dermatology. It publishes critical review articles and clinically focused original research covering comprehensive aspects of dermatological conditions. The journal enhances visibility and educational value through features like Key Points summaries, plain language summaries, and various digital elements, ensuring accessibility and depth for a diverse readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信